Eli Lilly and Company (NYSE:LLY) Trading Up 3.6% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s stock price shot up 3.6% during trading on Tuesday . The company traded as high as $924.14 and last traded at $918.12. 3,428,457 shares changed hands during mid-day trading, an increase of 8% from the average session volume of 3,173,018 shares. The stock had previously closed at $886.63.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo (orforglipron) expands Lilly’s obesity franchise, gives the company a daily oral GLP?1 with broad dosing convenience and a commercial launch scheduled for early April — a new revenue stream analysts peg at up to multi?billion dollars this year. Lilly’s weight-loss pill wins US approval
• Positive Sentiment: Bank of America and other sell?side notes view Foundayo as a strong, potentially preferred oral GLP?1 for Lilly and have reiterated/raised positive ratings and price targets — supporting upside expectations. Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1
• Neutral Sentiment: Lilly agreed to acquire Centessa (deal value up to ~$7.8B) to add sleep/wake and neuroscience assets — diversifies away from metabolic-only exposure but adds near-term cash outlay and integration risk. Market reaction has been mixed. Eli Lilly to Acquire Centessa Pharmaceuticals
• Neutral Sentiment: Lilly is also investing heavily in AI and neuroscience (multi?billion roadmap) — strategic for long?term pipeline growth but unlikely to move near?term earnings materially. Lilly’s Next Empire: A $10 Billion Bet on AI and Neuroscience
• Negative Sentiment: Rival Novo Nordisk released cross?trial comparisons saying Wegovy’s pill outperformed Foundayo on weight?loss and side effects — intensifying competitive narratives that can pressure expectations for Lilly’s pricing/market share. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1
• Negative Sentiment: Despite the approval, intraday weakness reflects broader market/geopolitical risk (headline?driven selling) and profit?taking after the prior rally — a common near?term drag on high?beta pharma names. Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh
• Negative Sentiment: Regulatory and pricing risk remains on the horizon — CEO comments opposing codification of recent drug?pricing deals and reports of potential tariffs add policy uncertainty that can weigh on valuation multiples. Eli Lilly opposes push to pass Trump drug-pricing deals into law

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research report on Monday, January 26th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,222.22.

Eli Lilly and Company Price Performance

The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $884.49 billion, a PE ratio of 40.74, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51. The stock’s 50-day moving average is $999.28 and its two-hundred day moving average is $966.87.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Old North State Trust LLC raised its stake in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Old North State Trust LLC now owns 7,414 shares of the company’s stock valued at $7,968,000 after acquiring an additional 27 shares in the last quarter. J. Derek Lewis & Associates Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $1,196,000. Purpose Unlimited Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $193,000. Stance Capital LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $1,480,000. Finally, Cornerstone Planning LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $4,226,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.